Dana-Farber Cancer Scientists to Use HistoRx's Biomarker Profiling Tech | GenomeWeb
NEW YORK (GenomeWeb News) – Researchers at the Dana-Farber/Harvard Cancer Center will use HistoRx’s Aqua biomarker profiling technology in cancer studies and cancer treatment research, the company said Thursday.
 
More than 900 researchers at DF/HCC will use the company’s PM-2000 tissue analysis tool, which was purchased by Brigham and Women’s Hospital for its pathology core facility in 2005.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.